Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction

Critical Care Medicine

Volumn 35, Issue 3, 2007, Pages 707-715

  Missant, Carlo ^a   Rex, Steffen ^a,b   Segers, Patrick ^c   Wouters, Patrick F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Hemodynamic processes; Levosimendan; Myocardial contraction; Myocardial ischemia; Pulmonary hypertension; Right ventricular dysfunction

Indexed keywords

LEVOSIMENDAN; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; ISCHEMIA; LABORATORY TEST; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY; SWINE; UNIVERSITY HOSPITAL; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HYDRAZONES; HYPERTENSION, PULMONARY; MYOCARDIAL CONTRACTION; PULMONARY ARTERY; PYRIDAZINES; STROKE VOLUME; SWINE; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 33947137368     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000257326.96342.57     Document Type: Article

References (49)

1. Davila-Roman VG, Waggoner AD, Hopkins WE, et al: Right ventricular dysfunction in low output syndrome after cardiac operations: Assessment by transesophageal echocardiography. Ann Thorac Surg 1995; 60:1081-1086
2. Mebazaa A, Karpati P, Renaud E, et al: Acute right ventricular failure - From pathophysiology to new treatments. Intensive Care Med 2004; 30:185-196
3. Lilleberg J, Nieminen MS, Akkila J, et al: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19:660-668
4. Pataricza J, Krassoi I, Hohn J, et al: Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17:115-121
5. Oldner A, Konrad D, Weitzberg E, et al: Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29:2185-2193
6. De Witt BJ, Ibrahim IN, Bayer E, et al: An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002; 94:1427-1433
7. Leather HA, Ver EK, Segers P, et al: Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 2003; 31: 2339-2343
8. Morelli A, De Castro S, Teboul JL, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31: 638-644
9. Morelli A, Teboul JL, Maggiore SM, et al: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 2006; 34:2287-2293
10. Toller WG, Stranz C: Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104:556-569
11. Starr I, Jeffers WA, Meade RH: The absence of conspicuous increments of venous pressure after severe damage to the right ventricle of the dog, with a discussion of the relation between clinical congestive failure and heart disease. Am Heart J 1943; 26:291-301
12. Wauthy P, Pagnamenta A, Vassalli F, et al: Right ventricular adaptation to pulmonary hypertension: An interspecies comparison. Am J Physiol Heart Circ Physiol 2004; 286: H1441-H1447
13. Piazza G, Goldhaber SZ: The acutely decompensated right ventricle: Pathways for diagnosis and management. Chest 2005; 128: 1836-1852
14. Burkhoff D, Mirsky I, Suga H: Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: A guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005; 289:H501-H512
15. Karunanithi MK, Michniewicz J, Copeland SE, et al: Right ventricular preload recruitable stroke work, end-systolic pressure-volume, and dP/dtmax-end-diastolic volume relations compared as indexes of right ventricular contractile performance in conscious dogs. Circ Res 1992; 70:1169-1179
16. Leeuwenburgh BP, Helbing WA, Steendijk P, et al: Biventricular systolic function in young lambs subject to chronic systemic right ventricular pressure overload. Am J Physiol Heart Circ Physiol 2001; 281:H2697-H2704
17. Dickstein ML, Yano O, Spotnitz HM, et al: Assessment of right ventricular contractile state with the conductance catheter technique in the pig. Cardiovasc Res 1995; 29:820-826
18. de Vroomen M, Steendijk P, Lopes Cardozo RH, et al: Enhanced systolic function of the right ventricle during respiratory distress syndrome in newborn lambs. Am J Physiol Heart Circ Physiol 2001; 280:H392-H400
19. Hettrick DA, Pagel PS, Warltier DC: Differential effects of isoflurane and halothane on aortic input impedance quantified using a three-element Windkessel model. Anesthesiology 1995; 83:361-373
20. Segers P, Verdonck P, Deryck Y, et al: Pulse pressure method and the area method for the estimation of total arterial compliance in dogs: Sensitivity to wave reflection intensity. Ann Biomed Eng 1999; 27:480-485
21. Naeije R: Pulmonary vascular resistance. A meaningless variable? Intensive Care Med 2003; 29:526-529
22. Brimioulle S, Maggiorini M, Stephanazzi J, et al: Effects of low flow on pulmonary vascular flow-pressure curves and pulmonary vascular impedance. Cardiovasc Res 1999; 42:183-192
23. Huez S, Retailleau K, Unger P, et al: Right and left ventricular adaptation to hypoxia: A tissue Doppler imaging study. Am J Physiol Heart Circ Physiol 2005; 289:H1391-H1398
24. Leeuwenburgh BP, Steendijk P, Helbing WA, et al: Indexes of diastolic RV function: Load dependence and changes after chronic RV pressure overload in lambs. Am J Physiol Heart Circ Physiol 2002; 282:H1350-H1358
25. Ludbrook J: Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994; 28:303-311
26. Ludbrook J: Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998; 25:1032-1037
27. Ghofrani HA, Rose F, Schermuly RT, et al: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002; 30:2489-2492
28. Morais RJ: Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth 2006; 20:82-84
29. Ukkonen H, Saraste M, Akkila J, et al: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68:522-531
30. Monchi M, Bellenfant F, Cariou A, et al: Early predictive factors of survival in the acute respiratory distress syndrome. A multivariate analysis. Am J Respir Crit Care Med 1998; 158:1076-1081
31. Pollesello P, Mebazaa A: ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care 2004; 10:436-441
32. Szilagyi S, Pollesello P, Levijoki J, et al: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486:67-74
33. Tassani P, Schad H, Heimisch W, et al: Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther 2002; 16:435-441
34. Haikala H, Kaivola J, Nissinen E, et al: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27:1859-1866
35. Haikala H, Nissinen E, Etemadzadeh E, et al: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995; 25: 794-801
36. Sonntag S, Sundberg S, Lehtonen LA, et al: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-2182
37. Parissis JT, Panou F, Farmakis D, et al: Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96:423-426
38. Dernellis J, Panaretou M: Effects of levosimendan on restrictive left ventricular filling in severe heart failure: A combined hemodynamic and Doppler echocardiographic study. Chest 2005; 128:2633-2639
39. De Luca L, Sardella G, Proietti P, et al: Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: A Doppler echocardiographic study. J Am Soc Echocardiogr 2006; 19:172-177
40. Kerbaul F, Rondelet B, Motte S, et al: Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004; 32:1035-1040
41. Sun JZ, Tang XL, Knowlton AA, et al: Late preconditioning against myocardial stunning. An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs. J Clin Invest 1995; 95:388-403
42. Bolli R: Myocardial "?stunning"? in man. Circulation 1992; 86:1671-1691
43. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ: Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: A series of cases. J Clin Pharmacol 2005; 45:704-708
44. Garcia Gonzalez MJ, Dominguez RA: Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: Potential role of levosimendan. Am J Cardiovasc Drugs 2006; 6:69-75
45. Nieminen MS, Akkila J, Hasenfuss G, et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912
46. Sandell EP, Hayha M, Antila S, et al: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26(Suppl 1):S57-S62
47. Antila S, Pesonen U, Lehtonen L, et al: Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004; 23:213-222
48. Kivikko M, Antila S, Eha J, et al: Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002; 42:43-51
49. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360:196-202